Just to clarify, since many still seem to be confused about this. It was the B-Arm of the N9831 trial that showed a 13-14% recurrance reduction for those receiving herceptin AFTER ACT vs. those who received ACT alone. The (international) HERA trial -- where patients receive herceptin for one or two years, or not at all, after ANY chemo combination (many received CEF, FEC, FAC, etc) -- showed a 46% reduction in recurrance between the treatment and observation arms. Please see the attached information:
HERA press release from ROCHE